Developing a Novel Risk-scoring System for Predicting Relapse in Patients with Ulcerative Colitis: A Prospective Cohort Study

Overview

Journal Pak J Med Sci

Specialty General Medicine

Date 2016 Feb 13

PMID 26870126

Citations 4

Authors

Seyed Vahid Hosseini

Ali Reza Safarpour

Seyed Alireza Taghavi

Affiliations

Soon will be listed here.

Abstract

Objectives: Ulcerative Colitis (UC) follows a natural clinical course of relapses and remissions. The aim of this study was to construct a risk-scoring formula in order to enable predicting relapses in patients with UC.

Methods: From October 2012 to October 2013, 157 patients from Shiraz, southern Iran who were diagnosed with UC and in remission were enrolled. At 3-month intervals, multiple risk factors of hemoglobin, complete blood counts, serum iron and albumin, erythrocyte sedimentation rate, and faecal calprotectin levels, sex, age, cigarette smoking, positive family history of inflammatory bowel diseases, past history of appendectomy, extra-intestinal accompanying diseases, extent of disease at the beginning of study, number of previous relapses, duration of disease and duration of remission before the study were assessed. Univariate and multivariate logistic regression were applied to fit the final model. The new risk-scoring system accuracy was assessed using receiver-operating-characteristics (ROC) curve analysis.

Results: Seventy four patients (48.1%) experienced a relapse. Multivariate analysis revealed that relapses could significantly be predicted by the level of fecal calprotectin (OR=8.1), age (OR=9.2), the Seo activity index (OR=52.7), and the number of previous relapses (OR=4.2). The risk scoring formula was developed using the regression coefficient values of the aforementioned variables.

Conclusion: Four predictor variables were significant in the final model and were used in our risk-scoring formula. It is recommended that patients who achieve high scores are diligently observed, treated, and followed up.

Citing Articles

and as prognostic markers for relapse in ulcerative colitis patients.

Mendes-Frias A, Moreira M, Vieira M, Gaifem J, Costa P, Lopes L Front Cell Infect Microbiol. 2024; 14:1367998.

PMID: 39027140 PMC: 11254828. DOI: 10.3389/fcimb.2024.1367998.

Epidemiologic profile of inflammatory bowel disease in Eastern Mediterranean Region (EMRO) countries: a systematic review and meta-analysis.

Momayez Sanat Z, Vahedi H, Malekzadeh R, Fanni Z BMC Public Health. 2024; 24(1):1395.

PMID: 38789987 PMC: 11127456. DOI: 10.1186/s12889-024-18816-z.

Development and Pilot Testing of an Online Calculation Tool for Relapse Risk Prediction in Ulcerative Colitis.

Safarpour A, Taghavi S, Shojaei-Zarghani S, Barati-Boldaji R Middle East J Dig Dis. 2023; 15(3):162-166.

PMID: 38023459 PMC: 10660315. DOI: 10.34172/mejdd.2023.338.

Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study.

Keshteli A, van den Brand F, Madsen K, Mandal R, Valcheva R, Kroeker K World J Gastroenterol. 2017; 23(21):3890-3899.

PMID: 28638229 PMC: 5467075. DOI: 10.3748/wjg.v23.i21.3890.

References

Bitton A, Dobkin P, Edwardes M, Sewitch M, Meddings J, Rawal S . Predicting relapse in Crohn's disease: a biopsychosocial model. Gut. 2008; 57(10):1386-92. DOI: 10.1136/gut.2007.134817. View

Desai D, Faubion W, Sandborn W . Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 25(3):247-55. DOI: 10.1111/j.1365-2036.2006.03184.x. View

Kallel L, Ayadi I, Matri S, Fekih M, Mahmoud N, Feki M . Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2009; 22(3):340-5. DOI: 10.1097/MEG.0b013e32832bab49. View

Hosseini S, Jafari P, Taghavi S, Safarpour A, Rezaianzadeh A, Moini M . Fecal Calprotectin is an Accurate Tool and Correlated to Seo Index in Prediction of Relapse in Iranian Patients With Ulcerative Colitis. Iran Red Crescent Med J. 2015; 17(2):e22796. PMC: 4353186. DOI: 10.5812/ircmj.22796. View

Osterman M, Aberra F, Cross R, Liakos S, McCabe R, Shafran I . Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014; 12(11):1887-93.e3. PMC: 4214893. DOI: 10.1016/j.cgh.2014.03.035. View

Lin L, Liu X, Wang D, Zheng C . Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. Medicine (Baltimore). 2015; 94(10):e556. PMC: 4602468. DOI: 10.1097/MD.0000000000000556. View

Jang E, Lee D, Kim J, Yang H, Lee S, Park Y . Age as a clinical predictor of relapse after induction therapy in ulcerative colitis. Hepatogastroenterology. 2009; 56(94-95):1304-9. View

TRUELOVE S, Witts L . Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955; 2(4947):1041-8. PMC: 1981500. DOI: 10.1136/bmj.2.4947.1041. View

Jahnsen J, Roseth A, Aadland E . [Measurement of calprotectin in faeces]. Tidsskr Nor Laegeforen. 2009; 129(8):743-5. DOI: 10.4045/tidsskr.08.0010. View

10.

Ho G, Mowat C, Goddard C, Fennell J, Shah N, Prescott R . Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004; 19(10):1079-87. DOI: 10.1111/j.1365-2036.2004.01945.x. View

11.

Colombel J, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y . Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011; 141(4):1194-201. DOI: 10.1053/j.gastro.2011.06.054. View

12.

Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M . An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992; 87(8):971-6. View

13.

Bitton A, Peppercorn M, Antonioli D, Niles J, Shah S, Bousvaros A . Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001; 120(1):13-20. DOI: 10.1053/gast.2001.20912. View

14.

Walsh A, Travis S . Assessing disease activity in patients with ulcerative colitis. Gastroenterol Hepatol (N Y). 2014; 8(11):751-4. PMC: 3966171. View

15.

Gisbert J, McNicholl A . Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2008; 41(1):56-66. DOI: 10.1016/j.dld.2008.05.008. View

16.

Costa F, Mumolo M, Ceccarelli L, Bellini M, Romano M, Sterpi C . Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005; 54(3):364-8. PMC: 1774401. DOI: 10.1136/gut.2004.043406. View

17.

Azad S, Sood N, Sood A . Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol. 2011; 17(3):194-8. PMC: 3122090. DOI: 10.4103/1319-3767.80383. View

18.

Bitton A, Sewitch M, Peppercorn M, Edwardes M, Shah S, Ransil B . Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol. 2003; 98(10):2203-8. DOI: 10.1111/j.1572-0241.2003.07717.x. View

19.

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier A, Chevaux J, Simon T . Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011; 141(5):1621-28.e1-5. DOI: 10.1053/j.gastro.2011.06.050. View

20.

Khalif I, Nanaeva B, Golovenko A, Golovenko O . [Long-term results of medical treatment in patients with a severe attack of ulcerative colitis]. Ter Arkh. 2015; 87(2):34-38. DOI: 10.17116/terarkh201587234-38. View